Tag: 杭州狼族419龙凤

first_img Facebook Twitter Login/Register With: Advertisement Advertisement A record seven female directors are presenting their films in the 20 high-profile Gala slots at the Toronto International Film Festival this month. It’s part of a festival milestone: nearly 30 per cent of all movies this year are directed by women.Among them is Maudie, a drama in the Special Presentation program, set in the 1930s and starring Sally Hawkins as the physically challenged Nova Scotia folk artist Maud Lewis, who has an unlikely romance with a reclusive man played by Ethan Hawke.“It’s a chick-heavy film and I want that to be shouted out to the world,” said producer Mary Young Leckie, en route to Colorado where Maudie was having its world premiere at the Telluride Film Festival. Advertisement Maudie is a 12-year passion project for Leckie, who produced the Canada-Ireland film along with Mary Sexton, Susan Mullen and Bob Cooper. Aisling Walsh directs from a script by Sherry White. LEAVE A REPLY Cancel replyLog in to leave a comment last_img read more

first_img 00:00 00:00 spaceplay / pause qunload | stop ffullscreenshift + ←→slower / faster ↑↓volume mmute ←→seek  . seek to previous 12… 6 seek to 10%, 20% … 60% XColor SettingsAaAaAaAaTextBackgroundOpacity SettingsTextOpaqueSemi-TransparentBackgroundSemi-TransparentOpaqueTransparentFont SettingsSize||TypeSerif MonospaceSerifSans Serif MonospaceSans SerifCasualCursiveSmallCapsResetSave SettingsSAN DIEGO (KUSI) – The “Yes For A Better San Diego” group turned in more than 114,000 signatures to the registrar this afternoon to get its convention center expansion initiative on the November ballot.The measure will have stiff competition on a crowded ballot. The November ballot will include two other high profile measures for developing the Mission Valley site, SoccerCity and SDSU West.KUSI’s Steve Bosh has the details. Categories: Local San Diego News, Politics FacebookTwitter Steve Bosh July 9, 2018 “Yes for a Better San Diego” turns in over 114,000 signatures in support of expanding the Convention Center Posted: July 9, 2018 Steve Bosh, last_img read more

first_imgHound Labs caught a boost in Series D funding to create a device it says can detect THC on a subject’s breath.  Canva A company looking to create the first THC breathalyzer said Tuesday it’s raised $30 million in Series D funding. Hound Labs is aiming to enable law enforcement and employers to conduct quick drug screenings with the device, which is on track to be released this winter. The device has raised concerns about accuracy and legal implications, however.  “In order to solve the challenge of determining recent marijuana use, we spent five years developing new technology that enables unparalleled low levels of detection in a portable device,” Hound Labs co-founder Dr. Mike Lynn said in a release earlier this year. “We have been testing this technology in collaboration with one of the world’s premier research universities. After years of research and development, we are excited to have validated the Hound science and technology that will advance our collective understanding of THC in breath.”In July, Hound Labs paid researchers to get 20 people high. Once the subjects smoked cannabis, researchers tested them and found THC could be detected in minute amounts in the breath after the subjects smoked. Hound Labs said the device can also detect THC ingested via cannabis-infused foods.  4 Marijuana tech is evolving Comments Share your voice Tags 5:37 Now playing: Watch this: Sci-Tech Politicslast_img read more

first_imgShares of Sun Pharmaceutical Industries rose by more than Rs 23 on the BSE on Tuesday morning and were trading at Rs 762 at about 1:45 pm responding to reports that the company was planning to buy Intas Pharmaceuticals for Rs 15,000 crore.The share had plunged about 4.5% on Monday after it said the US FDA issued a warning letter on its Halol plant in Gujarat after an inspection in September 2014 during which it found possible deviations from good manufacturing practices.If the deal goes through, it will mark the second-biggest acquisition for Sun Pharma after Ranbaxy, which was acquired for $4.5 billion in a stock deal.The proposed deal to acquire Intas Pharmaceuticals will entail a cash outgo of Rs 7,500 crore and the rest by way of stock,  DealStreetAsia quoted a source familiar with the development as saying. Ahmedabad-based Intas Pharma manufactures tablets, capsules, parenterals and cytotoxic formulations for the central nervous system (CNS), cardiovascular system, diabetology, gastroenterology, urology, pain management, animal health care, oncology and biotechnology, DealStreetAsia added.Sun Pharma has been acquiring and selling units over the past few weeks. Last week, it sold its manufacturing facility in Ohio, the US, to Nostrum Laboratories and in November this year, it bought American eyecare firm InSite Vision. Sun Pharma did not disclose the deal value for the sale of its Ohio facility, while saying the “financial impact” on the company was “negligible”.The company said it would cooperate with the US FDA for possible remedial measures at its Halol plant. “We will continue to cooperate with the US FDA and undertake any additional steps necessary to ensure that the US Agency is completely satisfied with our remediation of the Halol facility,” said Dilip Sanghvi, managing director, Sun Pharma, in a regulatory filing on 19 December. Meanwhile, Intas Pharmaceuticals is likely to come up with an IPO, having got market regulator Sebi’s nod for it. The IPO will give an opportunity for ChrysCapital to exit partially, after having failed twice, in 2011 and 2013, due to poor market conditions, said DealStreetAsia.last_img read more